Nifedipine: Difference between revisions
| Line 11: | Line 11: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Probably safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: no adjustment | ||
**Pediatric | **Pediatric: no adjustment | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 22:59, 26 June 2015
General
- Type: Calcium Channel Blocker, Dihydropyridine
- Dosage Forms: PO
- Common Trade Names: Procardia, Nifediac, Nifedical, Adalat, Afeditab
Adult Dosing
Preterm labor/Tocolysis
- 20mg x1, additional 20mg dose in 90min if ctx persist, followed by 20mg q3-8 hrs prn ctx
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation: Probably safe
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- galactose intolerance (lactose-containing forms)
- hypertensive crisis (IR form)
- HTN (IR form)
- caution if CHF
- caution if aortic stenosis
- caution if hypotension
- caution if renal impairment
- caution if hepatic impairment
- caution if anesthesia or surgery
- caution if concurrent or recent beta blocker use
- caution if GI stricture, severe (XL form)
- caution if GI hypomotility disorder (XL form)
- caution in elderly pts
Adverse Reactions
Serious
- CHF
- pulmonary edema
- MI
- arrhythmias
- hypotension, severe
- cholestasis
- allergic hepatitis
- angioedema
- anaphylaxis
- Stevens-Johnson syndrome
- exfoliative dermatitis
- toxic epidermal necrolysis
- exanthematous pustulosis, acute generalized
- GI obstruction (XL form)
- GI ulcer (XL form)
Common
- peripheral edema
- headache
- dizziness
- flushing
- fatigue/weakness
- nausea
- constipation
- muscle cramps
- nervousness
- palpitations
- dyspnea
- nasal congestion
- hypotension, transient
- eczematous eruptions (chronic use, elderly pts)
Pharmacology
- Half-life: 2h, 7h (ER)
- Metabolism: liver, CYP450: 3A4 substrate
- Excretion: urine 60-80% (<0.1% unchanged), bile/feces 20%
- Mechanism of Action: inhibits calcium ion influx into vascular smooth muscle and myocardium
